The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Paraplatin     azanide;cyclobutane-1,1- dicarboxylic...

Synonyms: Cbdca, carboplatin, JM-8, CCRIS 3404, JM 8, ...
This record was replaced with 2568.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of H2cbdca


Psychiatry related information on H2cbdca


High impact information on H2cbdca


Chemical compound and disease context of H2cbdca


Biological context of H2cbdca


Anatomical context of H2cbdca


Associations of H2cbdca with other chemical compounds


Gene context of H2cbdca

  • Loss of p53 function was selectively achieved by transduction of human papillomavirus 16 E6 (which degrades p53) into two drug-sensitive neuroblastoma cell lines with intact p53, causing high-level drug resistance to L-PAM, carboplatin, and etoposide [32].
  • The influence of these transporters on the pharmacodynamics of cisplatin, carboplatin, and oxaliplatin was investigated using human Menkes' disease fibroblasts (Me32a) that do not express either transporter and sublines molecularly engineered to express either ATP7A (MeMNK) or ATP7B (MeWND) [33].
  • These results indicate that a deficiency of FADD is involved in the insensitivity of tongue carcinoma cells for Fas activation, and that CBDCA treatment switches nonfunctional Fas to functional Fas by upregulation of FADD expression, resulting in activation of a Fas-sensitive pathway leading to apoptosis [34].
  • Neutralizing anti-Fas (APO-1/CD95) and anti-Fas ligand (FasL) antibodies obliterated the CBDCA-induced cell death [34].
  • MRP3 expression levels in the PMN rose rapidly within 24 hr after administration of CBDCA, whereas MRP4 expression levels remained the same [35].

Analytical, diagnostic and therapeutic context of H2cbdca


  1. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. Fanucchi, M., Glaspy, J., Crawford, J., Garst, J., Figlin, R., Sheridan, W., Menchaca, D., Tomita, D., Ozer, H., Harker, L. N. Engl. J. Med. (1997) [Pubmed]
  2. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. Smith, J.W., Longo, D.L., Alvord, W.G., Janik, J.E., Sharfman, W.H., Gause, B.L., Curti, B.D., Creekmore, S.P., Holmlund, J.T., Fenton, R.G. N. Engl. J. Med. (1993) [Pubmed]
  3. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. Chatelut, E., Canal, P., Brunner, V., Chevreau, C., Pujol, A., Boneu, A., Roché, H., Houin, G., Bugat, R. J. Natl. Cancer Inst. (1995) [Pubmed]
  4. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. Rusthoven, J., Levin, L., Eisenhauer, E., Mazurka, J., Carmichael, J., O'Connell, G., Bryson, P., Hirte, H., Koski, B. J. Natl. Cancer Inst. (1991) [Pubmed]
  5. Hypersensitivity reactions to carboplatin. Planner, R.S., Weerasiri, T., Timmins, D., Grant, P. J. Natl. Cancer Inst. (1991) [Pubmed]
  6. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Dooley, M.J., Poole, S.G., Rischin, D., Webster, L.K. Eur. J. Cancer (2002) [Pubmed]
  7. Carboplatin is ototoxic. Kennedy, I.C., Fitzharris, B.M., Colls, B.M., Atkinson, C.H. Cancer Chemother. Pharmacol. (1990) [Pubmed]
  8. Angiogenesis inhibitors in the treatment of lung cancer. Shepherd, F.A. Lung Cancer (2001) [Pubmed]
  9. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer. Olver, I.N., Stephenson, J., Schulze, D. Cancer Chemother. Pharmacol. (2000) [Pubmed]
  10. Onset and offset responses from inferior colliculus and auditory cortex to paired noisebursts: inner hair cell loss. Guo, Y., Burkard, R. Hear. Res. (2002) [Pubmed]
  11. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. Brugger, W., Heimfeld, S., Berenson, R.J., Mertelsmann, R., Kanz, L. N. Engl. J. Med. (1995) [Pubmed]
  12. Re: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. Malayeri, R. J. Natl. Cancer Inst. (2002) [Pubmed]
  13. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. Calais, G., Alfonsi, M., Bardet, E., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., Oudinot, P., Bertrand, P. J. Natl. Cancer Inst. (1999) [Pubmed]
  14. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. Marina, N.M., Rodman, J.H., Murry, D.J., Shema, S.J., Bowman, L.C., Jones, D.P., Furman, W., Meyer, W.H., Pratt, C.B. J. Natl. Cancer Inst. (1994) [Pubmed]
  15. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. Edmonson, J.H., McCormack, G.M., Wieand, H.S., Kugler, J.W., Krook, J.E., Stanhope, C.R., Everson, L.K., Laurie, J.A., Ebbert, L.P., Malkasian, G.D. J. Natl. Cancer Inst. (1989) [Pubmed]
  16. Corticosteroid modulation of interleukin-1 hematopoietic effects and toxicity in a murine system. Rinehart, J., Delamater, E.W., Keville, L., Measel, J. Blood (1994) [Pubmed]
  17. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. Meyer, W.H., Pratt, C.B., Poquette, C.A., Rao, B.N., Parham, D.M., Marina, N.M., Pappo, A.S., Mahmoud, H.H., Jenkins, J.J., Harper, J., Neel, M., Fletcher, B.D. J. Clin. Oncol. (2001) [Pubmed]
  18. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. Kosmidis, P., Mylonakis, N., Nicolaides, C., Kalophonos, C., Samantas, E., Boukovinas, J., Fountzilas, G., Skarlos, D., Economopoulos, T., Tsavdaridis, D., Papakostas, P., Bacoyiannis, C., Dimopoulos, M. J. Clin. Oncol. (2002) [Pubmed]
  19. A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium. Grégoire, V., Beauduin, M., Humblet, Y., Hamoir, M., Longueville, J., Majois, F., Remacle, F.M., Rousseau, F., Salamon, E., Wambersie, A. J. Clin. Oncol. (1991) [Pubmed]
  20. Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site. Naranda, T., Wong, K., Kaufman, R.I., Goldstein, A., Olsson, L. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  21. In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Ohwada, A., Rafii, S., Moore, M.A., Crystal, R.G. Blood (1996) [Pubmed]
  22. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Ulich, T.R., del Castillo, J., Yin, S., Swift, S., Padilla, D., Senaldi, G., Bennett, L., Shutter, J., Bogenberger, J., Sun, D. Blood (1995) [Pubmed]
  23. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Brugger, W., Henschler, R., Heimfeld, S., Berenson, R.J., Mertelsmann, R., Kanz, L. Blood (1994) [Pubmed]
  24. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. Motzer, R.J., Mazumdar, M., Gulati, S.C., Bajorin, D.F., Lyn, P., Vlamis, V., Bosl, G.J. J. Natl. Cancer Inst. (1993) [Pubmed]
  25. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. Rothenberg, M.L., Ostchega, Y., Steinberg, S.M., Young, R.C., Hummel, S., Ozols, R.F. J. Natl. Cancer Inst. (1988) [Pubmed]
  26. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Pertusini, E., Ratajczak, J., Majka, M., Vaughn, D., Ratajczak, M.Z., Gewirtz, A.M. Blood (2001) [Pubmed]
  27. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Twentyman, P.R., Wright, K.A., Mistry, P., Kelland, L.R., Murrer, B.A. Cancer Res. (1992) [Pubmed]
  28. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V.A., Egwuagu, C., Reed, E. J. Natl. Cancer Inst. (1992) [Pubmed]
  29. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. Iaffaioli, R.V., Tortoriello, A., Facchini, G., Caponigro, F., Gentile, M., Marzano, N., Gravina, A., Dimitri, P., Costagliola, G., Ferraro, A., Ferrante, G., De Marino, V., Illiano, A. J. Clin. Oncol. (1999) [Pubmed]
  30. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. Taylor, R.E., Bailey, C.C., Robinson, K., Weston, C.L., Ellison, D., Ironside, J., Lucraft, H., Gilbertson, R., Tait, D.M., Walker, D.A., Pizer, B.L., Imeson, J., Lashford, L.S. J. Clin. Oncol. (2003) [Pubmed]
  31. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Keshelava, N., Seeger, R.C., Groshen, S., Reynolds, C.P. Cancer Res. (1998) [Pubmed]
  32. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Keshelava, N., Zuo, J.J., Chen, P., Waidyaratne, S.N., Luna, M.C., Gomer, C.J., Triche, T.J., Reynolds, C.P. Cancer Res. (2001) [Pubmed]
  33. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Samimi, G., Katano, K., Holzer, A.K., Safaei, R., Howell, S.B. Mol. Pharmacol. (2004) [Pubmed]
  34. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Mishima, K., Nariai, Y., Yoshimura, Y. Int. J. Cancer (2003) [Pubmed]
  35. Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Oguri, T., Isobe, T., Fujitaka, K., Ishikawa, N., Kohno, N. Int. J. Cancer (2001) [Pubmed]
  36. Phase II evaluation of carboplatin in advanced endometrial carcinoma. Long, H.J., Pfeifle, D.M., Wieand, H.S., Krook, J.E., Edmonson, J.H., Buckner, J.C. J. Natl. Cancer Inst. (1988) [Pubmed]
  37. Acute promyelocytic leukaemia after treatment for seminoma with carboplatin. Snowden, J.A., Laidlaw, S.T., Champion, A.E., Reilly, J.T. Lancet (1994) [Pubmed]
WikiGenes - Universities